Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai

Amishi Panwar

doi:10.3389/fsoc.2023.1057220

Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai

Amishi Panwar

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Original language	English
Article number	1057220
Journal	Frontiers in Sociology
Volume	8
DOIs	https://doi.org/10.3389/fsoc.2023.1057220
Publication status	Published - 27 Jul 2023

Bibliographical note

Funding Information:
The research for this article was funded by the Graduate Institute Excellence Scholarship. Fieldwork for this research was supported by the Sylff Association, Tokyo Foundation for Policy Research and Professor Aditya Bharadwaj's European Research Council project (grant number: 313769) Red Revolution: The Emergence of Stem Cell Biotechnologies in India (2013–2018), based at the Graduate Institute of International and Development Studies (IHEID) in Geneva.

Funding Information:
I was a Research Assistant in India with a project titled “The Red Revolution: Emergence of Stem Cell Biotechnologies in India” based at the Geneva Graduate Institute, Switzerland and funded by the European Research Council (ERC) from 2014 to 2015. My fieldwork was supported by this project from 2015 to 2017. The study involved researching and archiving media reports, managing data and documenting, identifying available gray literature, writing reports, collecting and annotating relevant publications, and scoping the field for stem cell facilities in India. By stem cell facilities, I mean transplant and research centers, banks and their subsidiaries, and governing bodies in India. Among these, stem cell facilities were numerous private cord blood banks and a number of public cord blood banks. In India, umbilical cord blood stem cells are used to treat thalassemia, leukemia, and related blood disorders, whereas cord blood stem cell treatment for all other disorders is classified under research and requires registration of a clinical trial with the governing body in India.

Publisher Copyright:
Copyright © 2023 Panwar.

Access to Document

10.3389/fsoc.2023.1057220Licence: CC BY

Handle.net

Persistent link

1 Article (Academic Journal)

Corrigendum: Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai
Panwar, A., 21 Nov 2024, In: Frontiers in Sociology. 9, 1 p., 1508436.
Research output: Contribution to journal › Article (Academic Journal) › peer-review

Open Access

Cite this

@article{de34ba2ba013404197bb4c7edd850334,

title = "Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai",

author = "Amishi Panwar",

note = "Funding Information: The research for this article was funded by the Graduate Institute Excellence Scholarship. Fieldwork for this research was supported by the Sylff Association, Tokyo Foundation for Policy Research and Professor Aditya Bharadwaj's European Research Council project (grant number: 313769) Red Revolution: The Emergence of Stem Cell Biotechnologies in India (2013–2018), based at the Graduate Institute of International and Development Studies (IHEID) in Geneva. Funding Information: I was a Research Assistant in India with a project titled “The Red Revolution: Emergence of Stem Cell Biotechnologies in India” based at the Geneva Graduate Institute, Switzerland and funded by the European Research Council (ERC) from 2014 to 2015. My fieldwork was supported by this project from 2015 to 2017. The study involved researching and archiving media reports, managing data and documenting, identifying available gray literature, writing reports, collecting and annotating relevant publications, and scoping the field for stem cell facilities in India. By stem cell facilities, I mean transplant and research centers, banks and their subsidiaries, and governing bodies in India. Among these, stem cell facilities were numerous private cord blood banks and a number of public cord blood banks. In India, umbilical cord blood stem cells are used to treat thalassemia, leukemia, and related blood disorders, whereas cord blood stem cell treatment for all other disorders is classified under research and requires registration of a clinical trial with the governing body in India. Publisher Copyright: Copyright {\textcopyright} 2023 Panwar.",

year = "2023",

month = jul,

day = "27",

doi = "10.3389/fsoc.2023.1057220",

language = "English",

volume = "8",

journal = "Frontiers in Sociology",

issn = "2297-7775",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai

AU - Panwar, Amishi

N1 - Funding Information: The research for this article was funded by the Graduate Institute Excellence Scholarship. Fieldwork for this research was supported by the Sylff Association, Tokyo Foundation for Policy Research and Professor Aditya Bharadwaj's European Research Council project (grant number: 313769) Red Revolution: The Emergence of Stem Cell Biotechnologies in India (2013–2018), based at the Graduate Institute of International and Development Studies (IHEID) in Geneva. Funding Information: I was a Research Assistant in India with a project titled “The Red Revolution: Emergence of Stem Cell Biotechnologies in India” based at the Geneva Graduate Institute, Switzerland and funded by the European Research Council (ERC) from 2014 to 2015. My fieldwork was supported by this project from 2015 to 2017. The study involved researching and archiving media reports, managing data and documenting, identifying available gray literature, writing reports, collecting and annotating relevant publications, and scoping the field for stem cell facilities in India. By stem cell facilities, I mean transplant and research centers, banks and their subsidiaries, and governing bodies in India. Among these, stem cell facilities were numerous private cord blood banks and a number of public cord blood banks. In India, umbilical cord blood stem cells are used to treat thalassemia, leukemia, and related blood disorders, whereas cord blood stem cell treatment for all other disorders is classified under research and requires registration of a clinical trial with the governing body in India. Publisher Copyright: Copyright © 2023 Panwar.

PY - 2023/7/27

Y1 - 2023/7/27

U2 - 10.3389/fsoc.2023.1057220

DO - 10.3389/fsoc.2023.1057220

M3 - Article (Academic Journal)

C2 - 37577128

SN - 2297-7775

VL - 8

JO - Frontiers in Sociology

JF - Frontiers in Sociology

M1 - 1057220

ER -

Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai

Bibliographical note

Access to Document

Handle.net

Research output

Corrigendum: Thalassemia, biobanking infrastructures, and personalized stem cell therapies in Chennai

Cite this